Goldman Sachs Group, Inc. (The) set a €82.00 ($96.47) price objective on Sanofi SA (EPA:SAN) in a research report released on Tuesday, October 17th. The brokerage currently has a neutral rating on the stock.
A number of other brokerages also recently issued reports on SAN. BNP Paribas set a €83.00 ($97.65) price objective on Sanofi SA and gave the company a neutral rating in a report on Wednesday, September 6th. HSBC Holdings plc set a €81.00 ($95.29) price objective on Sanofi SA and gave the company a neutral rating in a report on Wednesday, August 30th. Jefferies Group LLC set a €87.00 ($102.35) price objective on Sanofi SA and gave the company a neutral rating in a report on Thursday, August 24th. Deutsche Bank AG set a €96.00 ($112.94) price objective on Sanofi SA and gave the company a buy rating in a report on Tuesday, August 1st. Finally, J P Morgan Chase & Co set a €90.00 ($105.88) price objective on Sanofi SA and gave the company a neutral rating in a report on Tuesday, August 1st. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the stock. Sanofi SA has an average rating of Hold and a consensus price target of €88.12 ($103.67).
Shares of Sanofi SA (EPA SAN) opened at 82.28 on Tuesday. The stock has a market capitalization of €103.32 billion and a PE ratio of 11.48. The firm has a 50-day moving average of €26.13 and a 200 day moving average of €26.03. Sanofi SA has a 1-year low of €24.55 and a 1-year high of €83.37.
ILLEGAL ACTIVITY NOTICE: “Goldman Sachs Group, Inc. (The) Analysts Give Sanofi SA (EPA:SAN) a €82.00 Price Target” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/10/28/sanofi-sa-san-pt-set-at-82-00-by-goldman-sachs-group-inc-the.html.
About Sanofi SA
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.